Evidence map›Paper›PMID 39962851›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report].

Xinyi Wang, Ning Mu, Mei Liu, Yue Xu, Shengnan Wu, Huan Lv, Chunhua Ma

Erratum issuedAbstract readCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Xinyi WangDepartment of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Ning MuDepartment of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Mei LiuDepartment of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Yue XuDepartment of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Shengnan WuDepartment of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Huan LvDepartment of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.
Chunhua MaDepartment of Oncology 5, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300121, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is a major cause of cancer-related mortality worldwide. Among patients with non-small cell lung cancer (NSCLC), approximately 3%-7% harbor anaplastic lymphoma kinase (ALK) gene fusions. In recent years, multiple tyrosine kinase inhibitors (TKIs) have significantly improved the survival of patients with metastatic ALK-positive NSCLC. However, disease progression due to resistance remains a challenge. This article retrospectively analyzes a case of advanced lung adenocarcinoma with the echinoderm microtubule associated protein like 4 (EML4)-ALK fusion variant 3 (V3). The patient developed resistance to Lorlatinib treatment accompanied by mesenchymal-epithelial transition factor (MET) amplification. Effective tumor control was achieved with the combined use of Crizotinib and Lorlatinib, providing a valuable reference for further exploration of treatment strategies following resistance to ALK-TKIs in clinical practice.
.

Indexed as

AdenocarcinomaCrizotinibDrug Resistance, NeoplasmLactamsLung NeoplasmsOncogene Proteins, FusionProto-Oncogene Proteins c-metPyrazolesAdenocarcinoma of LungAminopyridinesHumansProtein Kinase InhibitorsAminopyridinesCrizotinibEML4-ALK fusion protein, humanLactamslorlatinibOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-metPyrazolesALK gene fusionCrizotinibLorlatinibLung neoplasmsMET amplificationMolecularly targeted therapy

Identifiers

PMID39962851
PMCPMC11839500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.